Overview
Corporate Profile
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest News
View All
Jun 09, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June
Read More
Jun 07, 2021
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
Read More
May 12, 2021
Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference
Read More
May 11, 2021
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
Read More
May 04, 2021
Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast
Read More
Apr 07, 2021
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference
Read More
Mar 15, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read More
Mar 09, 2021
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
Read More
Mar 02, 2021
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast
Read More
Mar 01, 2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read More
Feb 16, 2021
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
Read More
Feb 09, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
Read More
Jan 11, 2021
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Read More
Dec 21, 2020
Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read More
Dec 17, 2020
Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares
Read More
Dec 14, 2020
Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
Read More
Upcoming Events
More events are coming soon.
Recent Events
Corporate Fact Sheet
Corporate Presentation
In the News
March 26, 2021
Source
Pharmacy Times
Investor & Media Contact
Josh Hamermesh
Chief Business Officer
Gamida Cell Ltd.
IRPR@gamida-cell.com